Adjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?-review of the open label phase III trial CONKO 005

被引：0
|
作者：
Wisniewski, Mathilde [1 ]
Placide, Pierre-Alain [1 ]
Granier, Sandra [1 ]
Al Shatti, Yacoub [1 ]
Al Qalaf, Shuaib [1 ]
Bouattour, Mohamed [1 ]
Lamuraglia, Michele [1 ]
Hammel, Pascal [1 ]
机构：
[1] Univ Denis Diderot Paris VII, AP HP, Hop Beaujon, Dept Digest & Med Oncol, Clichy, France
来源：
HEPATOBILIARY SURGERY AND NUTRITION | 2018年 / 7卷 / 05期
关键词：
RANDOMIZED CONTROLLED-TRIAL; CANCER; CHEMORADIOTHERAPY; MULTICENTER;
D O I：
10.21037/hbsn.2018.08.03
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：399 / 402
页数：4
相关论文
共 50 条
  • [1] CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial
    Sinn, Marianne
    Bahra, Marcus
    Liersch, Torsten
    Gellert, Klaus
    Messmann, Helmut
    Bechstein, Wolf
    Waldschmidt, Dirk
    Jacobasch, Lutz
    Wilhelm, Martin
    Rau, Bettina M.
    Gruetzmann, Robert
    Weinmann, Arndt
    Maschmeyer, Georg
    Pelzer, Uwe
    Stieler, Jens M.
    Striefler, Jana K.
    Ghadimi, Michael
    Bischoff, Sven
    Doerken, Bernd
    Oettle, Helmut
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3330 - +
  • [2] CONKO-005: Adjuvant therapy in R0 resected pancreatic cancer patients with gemcitabine plus erlotinib versus gemcitabine for 24 weeks-A prospective randomized phase III study
    Sinn, Marianne
    Liersch, Torsten
    Gellert, Klaus
    Messmann, Helmut
    Bechstein, Wolf O.
    Waldschmidt, Dirk
    Jacobasch, Lutz
    Wilhelm, Martin
    Rau, Bettina M.
    Gruetzmann, Robert
    Weinmann, Arndt
    Maschmeyer, Georg
    Pelzer, Uwe
    Stieler, Jens
    Striefler, Jana Kaethe
    Ghadimi, B. Michael
    Bahra, Marcus
    Oettle, Helmut
    Doerken, Bernd
    Riess, Hanno
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Adjuvant nab-Paclitaxel plus Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open -Label, Phase III Trial
    Tempero, Margaret A.
    Pelzer, Uwe
    O'Reilly, Eileen M.
    Winter, Jordan
    Oh, Do-Youn
    Li, Chung-Pin
    Tortora, Giampaolo
    Chang, Heung-Moon
    Lopez, Charles D.
    Bekaii-Saab, Tanios
    Ko, Andrew H.
    Santoro, Armando
    Park, Joon Oh
    Noel, Marcus S.
    Frassineti, Giovanni Luca
    Shan, Yan-Shen
    Dean, Andrew
    Riess, Hanno
    Van Cutsem, Eric
    Berlin, Jordan
    Philip, Philip
    Moore, Malcolm
    Goldstein, David
    Tabernero, Josep
    Li, Mingyu
    Ferrara, Stefano
    Le Bruchec, Yvan
    Zhang, George
    Lu, Brian
    Biankin, Andrew V.
    Reni, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (11) : 2007 - +
  • [4] A randomized phase II trial of adjuvant chemotherapy with uracil / tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer
    Yoshitomi, H.
    Togawa, A.
    Kimura, F.
    Shimizu, H.
    Yoshidome, H.
    Miyazaki, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] RANDOMIZED CROSS-OVER AIO PHASE III TRIAL COMPARING GEMCITABINE PLUS ERLOTINIB FOLLOWED BY CAPECITABINE VS. CAPECITABINE PLUS ERLOTINIB FOLLOWED BY GEMCITABINE IN ADVANCED PANCREATIC CANCER
    Boeck, S.
    Vehling-Kaiser, U.
    Waldschmidt, D.
    Kettner, E.
    Maerten, A.
    Winkelmann, C.
    Klein, S.
    Kojouharoff, G.
    Jung, A.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 233 - 233
  • [6] Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
    Zhu-Zeng Yin
    Zhi-Ming Zhao
    Wen-Bo Tang
    Nan Jiang
    Ke-Di Zhang
    Yu-Yao Song
    Yang Wang
    Cheng-Gang Li
    Yuan-Xing Gao
    Rong Liu
    World Journal of Clinical Cases, 2020, (13) : 2778 - 2786
  • [7] Adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for resected pancreatic ductal adenocarcinoma: A single center experience in China
    Yin, Zhu-Zeng
    Zhao, Zhi-Ming
    Tang, Wen-Bo
    Jiang, Nan
    Zhang, Ke-Di
    Song, Yu-Yao
    Wang, Yang
    Li, Cheng-Gang
    Gao, Yuan-Xing
    Liu, Rong
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (13) : 2778 - 2786
  • [8] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Bao, Philip Q.
    Ramanathan, Ramesh K.
    Krasinkas, Alyssa
    Bahary, Nathan
    Lembersky, Barry C.
    Bartlett, David L.
    Hughes, Steven J.
    Lee, Kenneth K.
    Moser, A. James
    Zeh, Herbert J., III
    ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (04) : 1122 - 1129
  • [9] Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer
    Philip Q. Bao
    Ramesh K. Ramanathan
    Alyssa Krasinkas
    Nathan Bahary
    Barry C. Lembersky
    David L. Bartlett
    Steven J. Hughes
    Kenneth K. Lee
    A. James Moser
    Herbert J. Zeh
    Annals of Surgical Oncology, 2011, 18 : 1122 - 1129
  • [10] Nab-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Resected Pancreatic Cancer in a Phase III Trial (APACT)
    Tempero, Margaret
    Cardin, Dana
    Biankin, Andrew V.
    Goldstein, David
    Moore, Malcolm
    O'Reilly, Eileen
    Philip, Philip
    Riess, Hanno
    Macarulla, Teresa
    Yung, Lotus
    Li, Mingyu
    Lu, Brian
    GASTROENTEROLOGY, 2015, 148 (04) : S944 - S944
12345